Oncotype DX Breast Recurrence Score

The Oncotype DX Test:
Prognosis + Prediction

Only the Oncotype DX test can identify patients who will and will not benefit from chemotherapy.1-5 EndoPredict® cannot.

The Oncotype DX Breast Recurrence Score test predicts both chemotherapy benefit and lack of benefit.1,2

EndoPredict lacks clinical evidence showing that patients with EPclin high-risk results will benefit from chemotherapy

EndoPredict test Breast Recurrence Score test
Evidence showing a statistically significant interaction between the test and treatment outcomes? NO YES2
Randomized, clinical trial data published? NO YES1,2
Validation studies in pre- and post-menopausal, node-negative patients? NO YES2,6,7
Meets highest level of evidence in recognized guidelines for treating invasive breast cancer? NO YES8,9

EndoPredict® may lead to unnecessary chemotherapy treatment based on its risk classification result

Many patients are categorized as EPclin high risk based on the EPclin algorithm*, which is strongly influenced by clinicopathologic features10

EndoPredict still has not been validated to show prediction of chemotherapy benefit

  • EndoPredict claims to be chemopredictive, but lacks randomized data within a homogenized cohort
  • EndoPredict does not stratify patients by nodal status, significantly skewing recurrence risks
  • Effect of chemotherapy does not vary between EPclin and EP molecular score results, suggesting that EndoPredict does not add any additional information beyond clinicopathologic features

Only the Oncotype DX Breast Recurrence Score® test has been proven to predict chemotherapy benefit in both node-negative and node-positive patients2,4


REFERENCES
  1. Sparano et al. N Engl J Med. 2018.
  2. Paik et al. J Clin Oncol. 2006.
  3. Sparano et al. N Engl J Med. 2015.
  4. Albain et al. Lancet Oncol. 2010.
  5. Geyer et al. npj Breast Cancer. 2018.
  6. Paik et al. N Engl J Med. 2004.
  7. Dowsett et al. J Clin Oncol. 2010.
  8. Telli et al. J Natl Compr Canc Netw. 2019.
  9. Andre et al. J Clin Oncol. 2019.
  10. Buus et al. J NatlCancer Inst. 2016.

*EPclin algorithm: nodal status + tumor size + EP (molecular score).

HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; NSABP B-20 = National Surgical Adjuvant Breast and Bowel Project; TAILORx = Trial Assigning Individualized Options for Treatment.

Prospective Outcomes:
TAILORxa

The Trial Assigning Individualized Options for Treatment included over 10,000 node negative patients.

Read Full Text

Order the Test

Order for HR+, HER2- patients to determine who will and will not benefit from chemotherapy.

Log In Now

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™